Cystic Fibrosis – Pipeline Review, H1 2015

Reference Code: GMDHC6132IDB
Publication Date: January 2015
# Table of Contents

Table of Contents.................................................................................................................. 2

List of Tables.................................................................................................................................. 13

List of Figures.................................................................................................................................. 15

Introduction..................................................................................................................................... 16

Global Markets Direct Report Coverage....................................................................................... 16

Cystic Fibrosis Overview............................................................................................................... 17

Therapeutics Development............................................................................................................ 18

Pipeline Products for Cystic Fibrosis – Overview......................................................................... 18

Pipeline Products for Cystic Fibrosis – Comparative Analysis....................................................... 19

Cystic Fibrosis – Therapeutics under Development by Companies............................................... 20

Cystic Fibrosis – Therapeutics under Investigation by Universities/Institutes............................... 26

Cystic Fibrosis – Pipeline Products Glance..................................................................................... 28

Late Stage Products ...................................................................................................................... 28

Clinical Stage Products ................................................................................................................ 29

Early Stage Products ...................................................................................................................... 30

Unknown Stage Products .............................................................................................................. 31

Cystic Fibrosis – Products under Development by Companies...................................................... 32

Cystic Fibrosis – Products under Investigation by Universities/Institutes..................................... 38

Cystic Fibrosis – Companies Involved in Therapeutics Development.......................................... 39

Actelion Ltd ................................................................................................................................ 39

Alaxia SAS ................................................................................................................................ 40

AlgiPharma AS .............................................................................................................................. 41

Arcturus Therapeutics, Inc ............................................................................................................ 42

Bayer AG .................................................................................................................................... 43

Beech Tree Labs, Inc. .................................................................................................................... 44

Carolus Therapeutics, Inc ............................................................................................................. 45

Celsius Therapeutics Plc ................................................................................................................ 46

Celtaxsys, Inc. ............................................................................................................................... 47

Chiesi Farmaceutici SpA ............................................................................................................... 48

Cilian AG ..................................................................................................................................... 49

Concert Pharmaceuticals, Inc ........................................................................................................ 50

Corbus Pharmaceuticals, Inc ......................................................................................................... 51

Cubist Pharmaceuticals, Inc ........................................................................................................... 52

DiscoveryBiomed, Inc. .................................................................................................................. 53

Errant Gene Therapeutics, LLC .................................................................................................... 54

Galapagos NV ............................................................................................................................... 55

GlaxoSmithKline plc ..................................................................................................................... 56

Grisons, S.A. ................................................................................................................................ 57

Invion Limited ............................................................................................................................... 58

InvivoGen Therapeutics ................................................................................................................. 59

JHL Biotech, Inc. ........................................................................................................................... 60

Kamada Ltd. .................................................................................................................................. 61
Cystic Fibrosis – Pipeline Review, H1 2015

Global Markets Direct

Lamellar Biomedical Ltd. ................................................................. 62
Laurent Pharmaceuticals Inc. .......................................................... 63
Microbion Corporation .................................................................. 64
Mucokineta Ltd. .......................................................................... 65
N30 Pharmaceuticals .................................................................... 66
NanoBio Corporation ..................................................................... 67
Nostrum Pharmaceuticals, LLC ....................................................... 68
Novabiotics Ltd. ........................................................................... 69
Novartis AG .................................................................................. 70
Ockham Biotech Limited ................................................................. 71
OSE Pharma SA ........................................................................... 72
Parion Sciences, Inc. ..................................................................... 73
Pfizer Inc. ..................................................................................... 74
Pharmaxis Limited ....................................................................... 75
Polyphor Ltd. ............................................................................... 76
Progenra, Inc. .............................................................................. 77
ProQR Therapeutics N.V. ............................................................... 78
Protalix BioTherapeutics, Inc. ......................................................... 79
PTC Therapeutics, Inc. ................................................................. 80
Pulmatrix, Inc. ............................................................................. 81
Reata Pharmaceuticals, Inc. ............................................................ 82
ReveraGen BioPharma, Inc. ............................................................ 83
Serendex Pharmaceuticals A/S ....................................................... 84
Shire Plc. ..................................................................................... 85
Synovo GmbH ........................................................................... 86
Verona Pharma Plc ....................................................................... 87
Vertex Pharmaceuticals Incorporated ............................................... 88
Xenetic Biosciences plc ............................................................... 89

Cystic Fibrosis – Therapeutics Assessment ........................................ 90
Assessment by Monotherapy Products ............................................. 90
Assessment by Combination Products ........................................... 91
Assessment by Target ................................................................ 92
Assessment by Mechanism of Action ............................................ 95
Assessment by Route of Administration ........................................ 98
Assessment by Molecule Type .................................................... 100

Drug Profiles ............................................................................. 102
(fosfomycin + tobramycin) - Drug Profile ..................................... 102
  Product Description ................................................................. 102
  Mechanism of Action ............................................................. 102
  R&D Progress ........................................................................ 102
alpha-1 proteinase inhibitor (human) second generation - Drug Profile ......................................................... 103
  Product Description ................................................................. 103
  Mechanism of Action ............................................................. 103
  R&D Progress ........................................................................ 103
Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis - Drug Profile
Product Description .................................................................................................................. 120
Mechanism of Action ............................................................................................................. 120
R&D Progress ......................................................................................................................... 120
dornase alfa biosimilar - Drug Profile
Product Description .............................................................................................................. 121
Mechanism of Action ............................................................................................................ 121
R&D Progress ......................................................................................................................... 121
Drug for Cystic Fibrosis - Drug Profile
Product Description ................................................................................................................ 122
Mechanism of Action ............................................................................................................ 122
R&D Progress ......................................................................................................................... 122
Drug to Activate Kir 4.2 for Cystic Fibrosis - Drug Profile
Product Description .............................................................................................................. 123
Mechanism of Action ............................................................................................................ 123
R&D Progress ......................................................................................................................... 123
Drugs for COPD and Cystic Fibrosis - Drug Profile
Product Description ................................................................................................................ 124
Mechanism of Action ............................................................................................................ 124
R&D Progress ......................................................................................................................... 124
Drugs for Cystic Fibrosis Lung Infections - Drug Profile
Product Description ................................................................................................................ 125
Mechanism of Action ............................................................................................................ 125
R&D Progress ......................................................................................................................... 125
EBX-001 - Drug Profile
Product Description ................................................................................................................ 126
Mechanism of Action ............................................................................................................ 126
R&D Progress ......................................................................................................................... 126
FDL-169 - Drug Profile
Product Description ................................................................................................................ 127
Mechanism of Action ............................................................................................................ 127
R&D Progress ......................................................................................................................... 127
fenretidine - Drug Profile
Product Description ................................................................................................................ 128
Mechanism of Action ............................................................................................................ 128
R&D Progress ......................................................................................................................... 128
fosfomycin - Drug Profile
Product Description ................................................................................................................ 129
Mechanism of Action ............................................................................................................ 129
R&D Progress ......................................................................................................................... 129
Gene Therapy to Activate CFTR for Cystic Fibrosis - Drug Profile
Product Description ................................................................................................................ 130
Mechanism of Action ............................................................................................................ 130
R&D Progress ......................................................................................................................... 130
MKA-104 - Drug Profile ................................................................. 148
Product Description ................................................................. 148
Mechanism of Action ............................................................... 148
R&D Progress ........................................................................... 148
molgramostim - Drug Profile .................................................... 149
Product Description ................................................................. 149
Mechanism of Action ............................................................... 149
R&D Progress ........................................................................... 149
N-1785 - Drug Profile ............................................................... 151
Product Description ................................................................. 151
Mechanism of Action ............................................................... 151
R&D Progress ........................................................................... 151
N-1861 - Drug Profile ............................................................... 152
Product Description ................................................................. 152
Mechanism of Action ............................................................... 152
R&D Progress ........................................................................... 152
N-6022 - Drug Profile ............................................................... 153
Product Description ................................................................. 153
Mechanism of Action ............................................................... 153
R&D Progress ........................................................................... 153
N-91115 - Drug Profile ............................................................ 154
Product Description ................................................................. 154
Mechanism of Action ............................................................... 154
R&D Progress ........................................................................... 154
N-91138 - Drug Profile ............................................................ 155
Product Description ................................................................. 155
Mechanism of Action ............................................................... 155
R&D Progress ........................................................................... 155
N-91169 - Drug Profile ............................................................ 156
Product Description ................................................................. 156
Mechanism of Action ............................................................... 156
R&D Progress ........................................................................... 156
nadolol - Drug Profile ............................................................... 157
Product Description ................................................................. 157
Mechanism of Action ............................................................... 157
R&D Progress ........................................................................... 157
NB-401 - Drug Profile .............................................................. 159
Product Description ................................................................. 159
Mechanism of Action ............................................................... 159
R&D Progress ........................................................................... 159
Next Generation Correctors - Drug Profile ......................... 160
Product Description ................................................................. 160
Mechanism of Action ............................................................... 160
R&D Progress ........................................................................... 160
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUR-118 - Drug Profile</td>
<td>174</td>
</tr>
<tr>
<td>Product Description</td>
<td>174</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>174</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>174</td>
</tr>
<tr>
<td>PUR-1900 - Drug Profile</td>
<td>175</td>
</tr>
<tr>
<td>Product Description</td>
<td>175</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>175</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>175</td>
</tr>
<tr>
<td>PUR-2000 - Drug Profile</td>
<td>176</td>
</tr>
<tr>
<td>Product Description</td>
<td>176</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>176</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>176</td>
</tr>
<tr>
<td>PXS-4728A - Drug Profile</td>
<td>177</td>
</tr>
<tr>
<td>Product Description</td>
<td>177</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>177</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>177</td>
</tr>
<tr>
<td>QBW-251 - Drug Profile</td>
<td>178</td>
</tr>
<tr>
<td>Product Description</td>
<td>178</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>178</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>178</td>
</tr>
<tr>
<td>QR-010 - Drug Profile</td>
<td>179</td>
</tr>
<tr>
<td>Product Description</td>
<td>179</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>179</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>179</td>
</tr>
<tr>
<td>Recombinant A1PI - Drug Profile</td>
<td>180</td>
</tr>
<tr>
<td>Product Description</td>
<td>180</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>180</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>180</td>
</tr>
<tr>
<td>Recombinant Enzyme for Cystic Fibrosis - Drug Profile</td>
<td>182</td>
</tr>
<tr>
<td>Product Description</td>
<td>182</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>182</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>182</td>
</tr>
<tr>
<td>Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Drug Profile</td>
<td>183</td>
</tr>
<tr>
<td>Product Description</td>
<td>183</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>183</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>183</td>
</tr>
<tr>
<td>Recombinant Human Follistatin - Drug Profile</td>
<td>184</td>
</tr>
<tr>
<td>Product Description</td>
<td>184</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>184</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>184</td>
</tr>
<tr>
<td>Recombinant Protein for Infectious Diseases and Respiratory Disorders - Drug Profile</td>
<td>185</td>
</tr>
<tr>
<td>Product Description</td>
<td>185</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>185</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>185</td>
</tr>
<tr>
<td>Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile</td>
<td>191</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>Product Description</td>
<td>191</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>191</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>191</td>
</tr>
<tr>
<td>Small Molecule for Cystic Fibrosis - Drug Profile</td>
<td>192</td>
</tr>
<tr>
<td>Product Description</td>
<td>192</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>192</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>192</td>
</tr>
<tr>
<td>Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis - Drug Profile</td>
<td>192</td>
</tr>
<tr>
<td>Product Description</td>
<td>192</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>192</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>192</td>
</tr>
<tr>
<td>Small Molecule to Activate CFTR Protein for Cystic Fibrosis - Drug Profile</td>
<td>193</td>
</tr>
<tr>
<td>Product Description</td>
<td>193</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>193</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>193</td>
</tr>
<tr>
<td>Small Molecule to Activate Nrf2 for Cystic Fibrosis - Drug Profile</td>
<td>194</td>
</tr>
<tr>
<td>Product Description</td>
<td>194</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>194</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>194</td>
</tr>
<tr>
<td>Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile</td>
<td>195</td>
</tr>
<tr>
<td>Product Description</td>
<td>195</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>195</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>195</td>
</tr>
<tr>
<td>Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD - Drug Profile</td>
<td>196</td>
</tr>
<tr>
<td>Product Description</td>
<td>196</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>196</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>196</td>
</tr>
<tr>
<td>Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis - Drug Profile</td>
<td>197</td>
</tr>
<tr>
<td>Product Description</td>
<td>197</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>197</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>197</td>
</tr>
<tr>
<td>Small Molecules for Cystic Fibrosis - Drug Profile</td>
<td>198</td>
</tr>
<tr>
<td>Product Description</td>
<td>198</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>198</td>
</tr>
<tr>
<td>R&amp;D Progress</td>
<td>198</td>
</tr>
<tr>
<td>Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile</td>
<td>199</td>
</tr>
<tr>
<td>Product Description</td>
<td>199</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>199</td>
</tr>
</tbody>
</table>
Cystic Fibrosis

Small Molecules to Activate CFTR for Cystic Fibrosis - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

Small Molecules to Inhibit USP8 for Cystic Fibrosis - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

solithromycin - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

SP-14 - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

SP-9 - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

tritovaquine - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

VBP-15 - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

VRT-325 - Drug Profile

- Product Description
- Mechanism of Action
- R&D Progress

VX-661 - Drug Profile

- Product Description
- Mechanism of Action
R&D Progress ........................................................................................................................................... 212
Cystic Fibrosis – Recent Pipeline Updates ........................................................................................... 213
Cystic Fibrosis – Dormant Projects ....................................................................................................... 252
Cystic Fibrosis – Discontinued Products .............................................................................................. 258
Cystic Fibrosis – Product Development Milestones ........................................................................... 259
Featured News & Press Releases ......................................................................................................... 259
  Jan 07, 2015: Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences .......... 259
  Dec 29, 2014: U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation ......................................................... 259
  Dec 19, 2014: Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie .. 260
  Dec 12, 2014: Galapagos selects second component of its investigational cystic fibrosis combination treatment ................ 261
  Dec 03, 2014: Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014 .......................................................... 261
  Dec 01, 2014: Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014 ........................................................................................................... 262
  Nov 05, 2014: Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation .................................................. 262
  Oct 30, 2014: Phase 3 Clinical Trial in Cystic Fibrosis Begins ............................................................... 263
  Oct 21, 2014: FDA Advisory Committee Recommends Approval of KALYDECO (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation ............................................ 264
  Oct 09, 2014: Galapagos presents novel cystic fibrosis combination therapy at NACFC .................. 264
Appendix .................................................................................................................................................. 266
  Methodology ....................................................................................................................................... 266
  Coverage ........................................................................................................................................... 266
  Secondary Research ............................................................................................................................ 266
  Primary Research ............................................................................................................................... 266
  Expert Panel Validation ....................................................................................................................... 266
  Disclaimer .......................................................................................................................................... 266
List of Tables

Number of Products under Development for Cystic Fibrosis, H1 2015 ................................................................. 18
Number of Products under Development for Cystic Fibrosis – Comparative Analysis, H1 2015 .............................. 19
Number of Products under Development by Companies, H1 2015 ........................................................................ 21
Number of Products under Development by Companies, H1 2015 (Contd..1) ......................................................... 22
Number of Products under Development by Companies, H1 2015 (Contd..2) ......................................................... 23
Number of Products under Development by Companies, H1 2015 (Contd..3) ......................................................... 24
Number of Products under Development by Companies, H1 2015 (Contd..4) ......................................................... 25
Number of Products under Investigation by Universities/Institutes, H1 2015 ......................................................... 27
Comparative Analysis by Late Stage Development, H1 2015 .............................................................................. 28
Comparative Analysis by Clinical Stage Development, H1 2015 ........................................................................ 29
Comparative Analysis by Early Stage Development, H1 2015 ............................................................................. 30
Comparative Analysis by Unknown Stage Development, H1 2015 ....................................................................... 31
Products under Development by Companies, H1 2015 ......................................................................................... 32
Products under Development by Companies, H1 2015 (Contd..1) ..................................................................... 33
Products under Development by Companies, H1 2015 (Contd..2) ..................................................................... 34
Products under Development by Companies, H1 2015 (Contd..3) ..................................................................... 35
Products under Development by Companies, H1 2015 (Contd..4) ..................................................................... 36
Products under Development by Companies, H1 2015 (Contd..5) ..................................................................... 37
Products under Investigation by Universities/Institutes, H1 2015 ......................................................................... 38
Cystic Fibrosis – Pipeline by Actelion Ltd, H1 2015 .............................................................................................. 39
Cystic Fibrosis – Pipeline by Alaxia SAS, H1 2015 .............................................................................................. 40
Cystic Fibrosis – Pipeline by AlipiPharma AS, H1 2015 .......................................................................................... 41
Cystic Fibrosis – Pipeline by Arcturus Therapeutics, Inc, H1 2015 ....................................................................... 42
Cystic Fibrosis – Pipeline by Bayer AG, H1 2015 .............................................................................................. 43
Cystic Fibrosis – Pipeline by Beech Tree Labs, Inc., H1 2015 ............................................................................... 44
Cystic Fibrosis – Pipeline by Carulos Therapeutics, Inc., H1 2015 ....................................................................... 45
Cystic Fibrosis – Pipeline by Celsius Therapeutics Plc, H1 2015 ........................................................................ 46
Cystic Fibrosis – Pipeline by Cellexsys, Inc., H1 2015 ......................................................................................... 47
Cystic Fibrosis – Pipeline by Chiesi Farmaceutici SpA, H1 2015 .......................................................................... 48
Cystic Fibrosis – Pipeline by Cilian AG, H1 2015 .............................................................................................. 49
Cystic Fibrosis – Pipeline by Concent Pharmaceuticals, Inc., H1 2015 ................................................................. 50
Cystic Fibrosis – Pipeline by Corbus pharmaceuticals, Inc., H1 2015 ................................................................. 51
Cystic Fibrosis – Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 ................................................................. 52
Cystic Fibrosis – Pipeline by DiscoveryBiomed, Inc., H1 2015 ........................................................................... 53
Cystic Fibrosis – Pipeline by Errant Gene Therapeutics, LLC, H1 2015 ............................................................. 54
Cystic Fibrosis – Pipeline by Galapagos NV, H1 2015 .......................................................................................... 55
Cystic Fibrosis – Pipeline by GlaxoSmithKline plc, H1 2015 .............................................................................. 56
Cystic Fibrosis – Pipeline by Grifols, S.A., H1 2015 ............................................................................................ 57
Cystic Fibrosis – Pipeline by Invion Limited, H1 2015 ......................................................................................... 58
Cystic Fibrosis – Pipeline by InvivoGen Therapeutics, H1 2015 ........................................................................ 59
Cystic Fibrosis – Pipeline by JHL Biotech, Inc., H1 2015 ..................................................................................... 60
Cystic Fibrosis – Pipeline by Kamada Ltd., H1 2015 .......................................................................................... 61
Cystic Fibrosis – Pipeline by Lamellar Biomedical Ltd, H1 2015 ................................. 62
Cystic Fibrosis – Pipeline by Laurent Pharmaceuticals Inc., H1 2015 .......................... 63
Cystic Fibrosis – Pipeline by Microbion Corporation, H1 2015 .................................. 64
Cystic Fibrosis – Pipeline by Mucokinetics Ltd., H1 2015 ......................................... 65
Cystic Fibrosis – Pipeline by N3O Pharmaceuticals, H1 2015 .................................... 66
Cystic Fibrosis – Pipeline by NanoBio Corporation, H1 2015 .................................. 67
Cystic Fibrosis – Pipeline by Nostrum Pharmaceuticals, LLC, H1 2015 ...................... 68
Cystic Fibrosis – Pipeline by Novabiotics Ltd, H1 2015 .......................................... 69
Cystic Fibrosis – Pipeline by Novartis AG, H1 2015 ................................................ 70
Cystic Fibrosis – Pipeline by Ockham Biotech Limited, H1 2015 .............................. 71
Cystic Fibrosis – Pipeline by Parion Pharma SA, H1 2015 .......................................... 72
Cystic Fibrosis – Pipeline by Pfizer Inc., H1 2015 ..................................................... 73
Cystic Fibrosis – Pipeline by Pharmaxis Sciences, Inc., H1 2015 ............................... 74
Cystic Fibrosis – Pipeline by Polyphor Ltd., H1 2015 ................................................ 75
Cystic Fibrosis – Pipeline by Progenra, Inc., H1 2015 ................................................ 76
Cystic Fibrosis – Pipeline by ProQR Therapeutics N.V., H1 2015 ............................... 77
Cystic Fibrosis – Pipeline by Protalix BioTherapeutics, Inc., H1 2015 ......................... 78
Cystic Fibrosis – Pipeline by PTC Therapeutics, Inc., H1 2015 ................................. 79
Cystic Fibrosis – Pipeline by Pulmatrix, Inc., H1 2015 .............................................. 80
Cystic Fibrosis – Pipeline by Reata Pharmaceuticals, Inc., H1 2015 ........................... 81
Cystic Fibrosis – Pipeline by RevaGen BioPharma, Inc., H1 2015 .............................. 82
Cystic Fibrosis – Pipeline by Serendex Pharmaceuticals A/S, H1 2015 ......................... 83
Cystic Fibrosis – Pipeline by Shire Plc, H1 2015 ....................................................... 84
Cystic Fibrosis – Pipeline by Synovo GmbH, H1 2015 .............................................. 85
Cystic Fibrosis – Pipeline by Verona Pharma Plc, H1 2015 ........................................ 86
Cystic Fibrosis – Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 ............ 87
Cystic Fibrosis – Pipeline by Xenetic Biosciences plc, H1 2015 ................................. 88
Assessment by Monotherapy Products, H1 2015 .................................................... 89
Assessment by Combination Products, H1 2015 ..................................................... 90
Number of Products by Stage and Target, H1 2015 .................................................. 91
Number of Products by Stage and Mechanism of Action, H1 2015 .......................... 92
Number of Products by Stage and Route of Administration, H1 2015 ....................... 93
Number of Products by Stage and Molecule Type, H1 2015 ..................................... 94
Cystic Fibrosis Therapeutics – Recent Pipeline Updates, H1 2015 ............................ 95
Cystic Fibrosis – Dormant Projects, H1 2015 .......................................................... 96
Cystic Fibrosis – Dormant Projects (Contd..1), H1 2015 ............................................ 97
Cystic Fibrosis – Dormant Projects (Contd..2), H1 2015 ............................................ 98
Cystic Fibrosis – Dormant Projects (Contd..3), H1 2015 ............................................ 99
Cystic Fibrosis – Dormant Projects (Contd..4), H1 2015 .......................................... 100
Cystic Fibrosis – Dormant Projects (Contd..5), H1 2015 .......................................... 101
Cystic Fibrosis – Discontinued Products, H1 2015 .................................................. 102

List of Figures

Number of Products under Development for Cystic Fibrosis, H1 2015 ................................................................. 18
Number of Products under Development for Cystic Fibrosis – Comparative Analysis, H1 2015 .......................... 19
Number of Products under Development by Companies, H1 2015 ........................................................................ 20
Number of Products under Investigation by Universities/Institutes, H1 2015 ......................................................... 26
Comparative Analysis by Late Stage Development, H1 2015 ................................................................................. 28
Comparative Analysis by Clinical Stage Development, H1 2015 ........................................................................ 29
Comparative Analysis by Early Stage Products, H1 2015 ....................................................................................... 30
Assessment by Monotherapy Products, H1 2015 ................................................................................................. 90
Number of Products by Top 10 Targets, H1 2015 ................................................................................................. 92
Number of Products by Stage and Top 10 Targets, H1 2015 ............................................................................... 92
Number of Products by Top 10 Mechanism of Actions, H1 2015 ................................................................. 95
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 ...................................................... 95
Number of Products by Top 10 Routes of Administration, H1 2015 .......................................................... 98
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 ............................................. 99
Number of Products by Top 10 Molecule Types, H1 2015 ............................................................................. 100
Number of Products by Stage and Top 10 Molecule Types, H1 2015 ......................................................... 101
Introduction

Global Markets Direct Report Coverage

Global Markets Direct's, 'Cystic Fibrosis - Pipeline Review, H1 2015', provides an overview of the Cystic Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic update following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Cystic Fibrosis Overview

Cystic fibrosis (CF) is an inherited disease of the mucus and sweat glands. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. The predisposing factors include family history and race (it is most common in white people of Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.
## Therapeutics Development

### Pipeline Products for Cystic Fibrosis – Overview

#### Number of Products under Development for Cystic Fibrosis, H1 2015

![Bar Chart]

Source: Global Markets Direct

<table>
<thead>
<tr>
<th>Stage of Development</th>
<th>Number of Products Under Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Registration</td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td></td>
</tr>
<tr>
<td>Phase II</td>
<td></td>
</tr>
<tr>
<td>Phase I</td>
<td></td>
</tr>
<tr>
<td>Preclinical</td>
<td></td>
</tr>
<tr>
<td>Discovery</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
</tr>
</tbody>
</table>

Source: Global Markets Direct
Pipeline Products for Cystic Fibrosis – Comparative Analysis

Number of Products under Development for Cystic Fibrosis – Comparative Analysis, H1 2015

<table>
<thead>
<tr>
<th>Stage of Development</th>
<th>Company</th>
<th>Universities/Institutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preclinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Global Markets Direct
Cystic Fibrosis – Therapeutics under Development by Companies

Number of Products under Development by Companies, H1 2015

Source: Global Markets Direct
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Pre-Registration</th>
<th>Phase III</th>
<th>Phase II</th>
<th>Phase I</th>
<th>Phase 0</th>
<th>IND/CTA Filed</th>
<th>Preclinical</th>
<th>Discovery</th>
<th>Unknown</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actelion Ltd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advanced Inhalation Therapies (AIT) Ltd.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alaxia SAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AlgiPharma AS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arcturus Therapeutics, Inc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bayer AG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beech Tree Labs, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carolus Therapeutics, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celcis Therapeutics Plc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celtaxsys, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cilian AG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concert Pharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corbus pharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cubist Pharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CURx Pharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Global Markets Direct
### Number of Products under Development by Companies, H1 2015 (Contd..1)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Pre-Registration</th>
<th>Phase III</th>
<th>Phase II</th>
<th>Phase I</th>
<th>Phase 0</th>
<th>IND/CTA Filed</th>
<th>Preclinical</th>
<th>Discovery</th>
<th>Unknown</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>EnBiotix, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Errant Gene Therapeutics, LLC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flatley Discovery Lab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Galapagos NV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GlaxoSmithKline plc</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grifols, S.A.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invion Limited</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>InvivoGen Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JHL Biotech, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamada Ltd.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamellar Biomedical Ltd</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laurent Pharmaceuticals Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbion Corporation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucokinetica Ltd.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NanoBio Corporation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Global Markets Direct
Appendix

Methodology

Global Markets Direct's dedicated Research and Analysis Teams consist of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise.

Global Markets Direct adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the Strategic and Competitive Intelligence Professionals (www.scip.org).

All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports.

Coverage

The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible.

The report covers all the pharmaceutical/biopharmaceutical products under development across the globe. The scope of the pipeline products coverage aims at setting up the boundaries of the project. It comprises all the therapeutic products that are in the course of development, however, if a drug is solely used for research purpose, where the intention for its further development as a drug is not clear or the strategy for commercialization is not known, the drug is not included in the report. Global Markets Direct aims to cover major news events and deals in the pharmaceutical industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).

Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out to source/update the pipeline products information. The secondary research sources that are typically referred to include, but are not limited to: Company websites, annual reports, financial reports, company pipeline chart, broker reports, investor presentations and SEC filings, journals and conferences, clinical trials registries, internal proprietary databases, news articles, press releases and web-casts specific to the companies operating in the respective indication/therapy area.

Primary Research

Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its pipeline products data. A typical research interview provides first-hand information on the pipeline therapeutics landscape and helps in validating and strengthening the secondary research findings. Primary research involves email interactions with the industry participants across geographies. The participants who typically take part in such a process include, but are not limited to: CEOs, VPs, business development managers, market intelligence managers and national sales managers.

Expert Panel Validation

Global Markets Direct uses a panel of experts to cross verify research methodologies, and drive its analytical content. The Global Markets Direct expert panel comprises senior research managers, marketing managers, product specialists & international sales managers.

Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global Markets Direct.